Chiara Lagorio: the Strategic Role of Lifestyle in the Management of Dyslipidemia
Chiara Lagorio, Research Dietitian at Candiolo Cancer Institute IRCCS, posted on LinkedIn:
“2025 European Society of Cardiology /European Atherosclerosis Society guidelines: the strategic role of lifestyle in the management of dyslipidemia.
The 2025 Focused Update of these LG ESC/EAS strongly confirms that prevenzione cardiovascolare can no longer be seen as a “lifestyle or drug therapy”, but as a real integrazione between risk assessment, nutritional intervention and pharmacological treatment when appropriate.
⸻
1. Risk assessment: the starting point
- New SCORE2 and SCORE2-OP algorithms: estimate the risk of fatal and non-fatal CV events up to 89 years.
- Introduction of risk modifiers (coronary calcium, vascular imaging) in borderline cases.
- The focus shifts from the single lipid value to the global cardiovascular risk profile: essential for deciding how much to focus on lifestyle and when to combine drug therapy.
⸻
2. Lifestyle: not an alternative, but the basis of treatment
- Diet, physical activity, weight control and fumo are at the forefront of all patients, at any risk level.
- Recommended model: DietaMediterranea → high in fiber and unsaturated fats, low in saturated fats and free sugars.
- Supplements not recommended in the absence of clinical evidence on cardiovascular events.
- As dietisti, our role is to ensure adherence, personalization and continuity over time.
⸻
3. Drug therapy: when lifestyle is not enough
- In high- and very high-risk patients, an early and strong strike approach is indicated.
- LDL -cholesterol confirmed as a causal factor of atherosclerosis: if the target is not reached, it is supplemented with statins ± ezetimibe ± PCSK9 or bempedoic acid inhibitors.
- Our contribution is critical to optimizing efficacy, reducing adverse metabolic effects, and improving aderenza.
⸻
4. Practical implications for us nutrition professionals
- Evaluate the patient in terms of overall cardiovascular risk, not just cholesterol values.
- Propose lifestyle as a terapia and not as simple advice.
- Collaborate with the doctor when drug therapy is indicated, with a view to therapeutic sinergia.
- Educare the patient to see prevention as a percorsointegrato, personalized and continuous.
⸻
In summary: effective cardiovascular prevenzione arises from the integration of lifestyle and risk-driven drug treatment. As nutrition professionals, we are an active part of the team in dislipidemie management and aterosclerosi prevention.
Source: Mach F, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2025; doi:10.1093/eurheartj/ehaf190.”
Title: 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
Authors: François Mach, Konstantinos C Koskinas, Jeanine E Roeters van Lennep, Lale Tokgözoğlu, Lina Badimon, Colin Baigent, Marianne Benn, Christoph J Binder, Alberico L Catapano, Guy G De Backer, Victoria Delgado, Natalia Fabin, Brian A Ference, Ian M Graham, Ulf Landmesser, Ulrich Laufs, Borislava Mihaylova, Børge Grønne Nordestgaard, Dimitrios J Richter, Marc S Sabatine, ESC/EAS Scientific Document Group
Read full article here.
Stay informed with Hemostasis Today.
-
Apr 7, 2026, 14:50Sean O.: The Urgent Need for Blood in the United States
-
Apr 7, 2026, 14:42Samson Kraikue-Quaicoe: The Role of Minor Fractions in Advanced Medical Care Beyond Whole Blood and Primary Components
-
Apr 7, 2026, 14:36Heghine Khachatryan: When Bleeding Speaks – Think Beyond Gynecology
-
Apr 7, 2026, 13:50Annie Bauzon: How to Properly Make a Peripheral Blood Smear
-
Apr 7, 2026, 13:42Timothy Lesaca: How SSRIs Influence Hemostasis Through Platelets
-
Apr 7, 2026, 13:32Bastu Odoka: Storage Lesions – What Really Happens to Stored Blood
-
Apr 7, 2026, 13:15Mehmet Semin Çakir: Ticagrelor-Based Dual Antiplatelet Therapy in Stent Assisted Endovascular Treatment
-
Apr 6, 2026, 16:39Dhinesh Selvaraju: FDA Approves Narsoplimab (Yartemlea) as 1st Treatment for TA-TMA in Adults and Children
-
Apr 6, 2026, 16:38Linda Vorberg: A Detailed Analysis on The Usefulness of CT for DL-Based Stroke Lesion Segmentation